On peptides,
longevity,
and the evidence.
I read the primary literature on peptide pharmacology and longevity science, and I write what the controlled evidence does and doesn't show. Signed. Cited. Not medical advice.
Long-form reference work runs on peptidehackerlab.com. This site is the bylined commentary layer: shorter, more opinionated, anchored on individual trials and review articles when the evidence is worth a take.
Recent commentary
All articles →Tirzepatide Muscle Loss Is the Wrongly Framed Question
The recruiting GRAMS trial is not a result. It is a better question. By measuring DXA fat-free mass, thigh MRI muscle quality, and bone turnover markers, NCT07154719 can clarify what the GLP-1 body-composition debate keeps flattening.
Senolytics for the Aging Eye: The Evidence Is Mostly Mice
A new review in Biogerontology places senolytic agents alongside gene editing and stem cells as high-priority interventions for AMD, cataracts, and dry eye. The mechanistic case is solid. The clinical evidence for the eye specifically is almost entirely preclinical, and that gap matters.
Semaglutide on TikTok: Popularity Doesn't Track Quality
A cross-platform study of 200 semaglutide videos on TikTok and Bilibili finds that user engagement metrics are nearly useless as a proxy for information quality. The implication for public health is uncomfortable: the platforms' own ranking logic actively undermines health literacy.
Tirzepatide Raises Calcitonin Modestly, MTC Remains Unproven
A Greek research group reports short-term serum calcitonin changes on tirzepatide in adults with obesity. The elevations fit the known pharmacology, but no MTC cases have appeared in any trial. The question is not whether calcitonin rises. It does. The question is whether that rise means anything clinically.
What I cover
- GHRH analogs
- Sermorelin, tesamorelin, CJC-1295, and the pulsatile growth-hormone literature.
- GLP-1 receptor agonists
- Semaglutide, tirzepatide, retatrutide — body-composition, hepatic, and cardiovascular endpoints in 2025–2026 trials.
- Tissue-repair peptides
- BPC-157, TB-500, GHK-Cu, and the persistent gap between preclinical and human evidence.
- Mitochondrial and longevity peptides
- MOTS-c, SS-31, NAD+, Epithalon — what the literature claims versus what controlled trials demonstrate.